ClinicalTrials.gg
CompletedNCT02809183Updated Jan 14, 2020Results posted

Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis

A Phase 1/2 interventional study of Placebo and TRC101 in Acidosis, sponsored by Tricida, Inc.. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-01-14.

Sponsored by Tricida, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2016, registered Jun 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This was a double-blind, placebo-controlled, parallel-design, 6-arm, fixed dose study. The study enrolled 135 adult male and female subjects with Stage 3 or 4 chronic kidney disease and low serum bicarbonate levels. The study was conducted in two parts. In Part 1 study drug dosing (TRC101 or placebo) continued for 14 days twice daily (BID). In Part 2 study drug dosing (TRC101 or placebo) continued for 14 days once daily (QD).

The maximum study duration per subject was anticipated to be up to 42 days.

02

Conditions studied

  • Acidosis

Keywords

  • metabolic acidosis
  • serum bicarbonate
  • kidney disease
03

In context

Acidosis

111 studies on the registry are indexed under Acidosis; 19 are open to participants now.

This study's enrollment of 135 is above the median of 52 across 79 interventional studies indexed under Acidosis.

Browse Acidosis studies →

Lead sponsor

Tricida, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Estimated (eGFR) of 20 to \<60 mL/min/1.73m2
  • Serum bicarbonate level of 12 to 20 mEq/L

Exclusion criteria

Exclusion Criteria:

  • Any level of low serum bicarbonate that, in the opinion of the Investigator, requires emergency intervention.
  • Severe comorbid conditions other than chronic kidney disease.
  • .
  • Anticipated changes in doses of any of the following drugs or drug classes: diuretics, non-ophthalmic carbonic anhydrase inhibitors, oral diabetes drugs, antihypertensive drugs, antacids, H2-blockers, or proton pump inhibitors.
  • Excluded drugs or drug classes: insulin, non-daily or "as needed" diuretics, herbal products, dietary supplements, multivitamins, naturopathic remedies, sodium bicarbonate, potassium citrate, sodium citrate or other alkali therapy, non-steroidal anti-inflammatory drugs (NSAIDs), fiber supplements, laxatives, calcium and magnesium supplements, or electrolyte binders and other binder drugs.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
135 participants (actual)

Study arms

  • Placebo comparator
    Placebo-BID

    Administered twice daily (BID) for 14 days

    Drug: Placebo

  • Experimental
    TRC101 (1.5g BID)

    Administered twice daily (BID) for 14 days

    Drug: TRC101

  • Experimental
    TRC101 (3g BID)

    Administered twice daily (BID) for 14 days

    Drug: TRC101

  • Experimental
    TRC101 (4.5g BID)

    Administered twice daily (BID) for 14 days

    Drug: TRC101

  • Experimental
    TRC101 (6g QD)

    Administered once daily (QD) for 14 days

    Drug: TRC101

  • Placebo comparator
    Placebo-QD

    Administered once daily (QD) for 14 days

    Drug: Placebo

Interventions

  • DrugPlacebo

    oral suspension

  • DrugTRC101

    oral suspension

    Also known as: Veverimer

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE

    The number and percentage of subjects who reported treatment-emergent adverse events (TEAEs) summarized by system organ class and preferred term (see Reported Adverse Events) as well as by severity, causality, seriousness, and action taken with regard to study drug. All analyses were descriptive.

    Time frame: Through treatment period completion (Day 15)

  2. Change From Baseline to the End of Treatment (Day 15) in Serum Bicarbonate Within Each Individual TRC101 Dose Group

    Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline

    Time frame: Baseline and Day 15

Secondary outcomes

  1. Comparison of Change From Baseline in Serum Bicarbonate at Day 15 Between Each TRC101 Dose Group Versus Placebo

    Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for each TRC101 dose group versus that for Placebo

    Time frame: Baseline and Day 15

  2. Change From Baseline in Serum Bicarbonate at Day 15 Within the Combined TRC101 Treatment Group

    Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline

    Time frame: Baseline and Day 15

  3. Comparison of Change From Baseline in Serum Bicarbonate at Day 15 Between the Combined TRC101 Treatment Group Versus Placebo

    Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the Combined TRC101 Treatment Group versus that for Placebo

    Time frame: Baseline and Day 15

  4. Comparison of the Proportion of Subjects Whose Serum Bicarbonate Values Increased From Baseline to Day 15 by Greater Than or Equal to 2, 3, or 4 mEq/L Between Each TRC101 Dose Group Versus Placebo

    Comparison of the proportion of subjects whose serum bicarbonate values increased from Baseline to Day 15 by greater than or equal to 2, 3, or 4 mEq/L between each TRC101 BID Dose Group versus Placebo

    Time frame: Baseline and Day 15

  5. Change From Baseline in Serum Bicarbonate at Day 15 Within the TRC101 6g QD Dose Group

    Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline

    Time frame: Baseline and Day 15

  6. Change From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus Placebo

    Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the TRC101 6g dose group versus that for Placebo

    Time frame: Baseline and Day 15

  7. Change From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus the TRC101 3g BID Dose Group

    Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the TRC101 6g QD dose group versus that for the TRC101 3g BID dose group

    Time frame: Baseline and Day 15

  8. Comparison of the Proportion of Subjects in the TRC101 6g QD Dose Group Whose Serum Bicarbonate Values Increased From Baseline to Day 15 by Greater Than or Equal to 2, 3, or 4 mEq/L Versus Placebo

    Comparison of the proportion of subjects whose serum bicarbonate values increased from Baseline to Day 15 by greater than or equal to 2, 3, or 4 mEq/L between the 6g TRC101 QD Dose Group versus Placebo

    Time frame: Baseline and Day 15

07

Results

Posted Jan 14, 2020

Participant flow

Participant flow — Overall Study
MilestonePlacebo BID1.5g TRC101 BID3g TRC101 BID4.5g TRC101 BIDPlacebo QD6g TRC101 QD
Started25252526628
Completed25252526628
Not completed000000

Outcome measures

PrimaryNumber of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE

The number and percentage of subjects who reported treatment-emergent adverse events (TEAEs) summarized by system organ class and preferred term (see Reported Adverse Events) as well as by severity, causality, seriousness, and action taken with regard to study drug. All analyses were descriptive.

Time frame:
Through treatment period completion (Day 15)
Reported as:
Count of participants · Participants
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE
ParticipantsPooled Placebo1.5g TRC101 BID3g TRC101 BID4.5g TRC101 BID6g TRC101 QD
Subjects Reporting any TEAE141391717
≥ 1 Mild TEAE11981415
≥ 1 Moderate TEAE34132
≥ 1 Severe TEAE00000
≥ 1 Serious TEAE00000
Study Drug Discontinuation Due to TEAE00000
PrimaryChange From Baseline to the End of Treatment (Day 15) in Serum Bicarbonate Within Each Individual TRC101 Dose Group

Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline

Time frame:
Baseline and Day 15
Reported as:
Least squares mean · mEq/L
Change From Baseline to the End of Treatment (Day 15) in Serum Bicarbonate Within Each Individual TRC101 Dose Group
mEq/LPooled Placebo1.5g TRC101 BID3g TRC101 BID4.5g TRC101 BID
Change From Baseline to the End of Treatment (Day 15) in Serum Bicarbonate Within Each Individual TRC101 Dose Group-0.2 ± 0.43.2 ± 0.43.0 ± 0.43.7 ± 0.4
Statistical analysis
  • Pooled Placebo · Mixed Models Analysis · p = 0.5547 (The null hypothesis is that the mean change from baseline within the Pooled Placebo treatment group = 0 mEq/L.) · Group ls mean: -0.2 · 95% CI -0.9 to 0.5
  • 1.5g TRC101 BID · Mixed Models Analysis · p = < 0.0001 (The null hypothesis is that the mean change from baseline within the 1.5g TRC101 BID group = 0 mEq/L) · Group ls mean: 3.2 · 95% CI 2.4 to 4.0
  • 3g TRC101 BID · Mixed Models Analysis · p = < 0.0001 (The null hypothesis is the 3g TRC101 BID treatment group mean change from baseline = 0 mEq/L.) · Group ls mean: 3.0 · 95% CI 2.2 to 3.8
  • 4.5g TRC101 BID · Mixed Models Analysis · p = < 0.0001 (The null hypothesis is the 4.5g TRC101 BID treatment group mean change from baseline = 0 mEq/L) · Group ls mean: 3.7 · 95% CI 2.9 to 4.5
SecondaryComparison of Change From Baseline in Serum Bicarbonate at Day 15 Between Each TRC101 Dose Group Versus Placebo

Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for each TRC101 dose group versus that for Placebo

Time frame:
Baseline and Day 15
Reported as:
Least squares mean · mEq/L
Comparison of Change From Baseline in Serum Bicarbonate at Day 15 Between Each TRC101 Dose Group Versus Placebo
mEq/LPooled Placebo1.5g TRC101 BID3g TRC101 BID4.5g TRC101 BID
Comparison of Change From Baseline in Serum Bicarbonate at Day 15 Between Each TRC101 Dose Group Versus Placebo-0.2 ± 0.43.2 ± 0.43.0 ± 0.43.7 ± 0.4
Statistical analysis
  • Pooled Placebo vs 1.5g TRC101 BID · Mixed Models Analysis · p = < 0.0001 (The null hypothesis is the difference between treatment groups (1.5g TRC101 BID - Pooled Placebo) in the mean change from baseline = 0 mEq/L.) · Difference between group ls means: 3.4 · 95% CI 2.3 to 4.5
  • Pooled Placebo vs 3g TRC101 BID · Mixed Models Analysis · p = < 0.0001 (The null hypothesis is the difference between treatment groups (3g TRC101 BID - Pooled Placebo) in the mean change from baseline = 0 mEq/L.) · Difference between group ls means: 3.2 · 95% CI 2.2 to 4.3
  • Pooled Placebo vs 4.5g TRC101 BID · Mixed Models Analysis · p = < 0.0001 (The null hypothesis is the difference between the treatment groups (4.5g TRC101 BID - Pooled Placebo) in the mean change from baseline = 0 mEq/L.) · Difference between group ls means: 3.9 · 95% CI 2.9 to 5.0
SecondaryChange From Baseline in Serum Bicarbonate at Day 15 Within the Combined TRC101 Treatment Group

Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline

Time frame:
Baseline and Day 15
Reported as:
Least squares mean · mEq/L
Change From Baseline in Serum Bicarbonate at Day 15 Within the Combined TRC101 Treatment Group
mEq/LCombined TRC101
Change From Baseline in Serum Bicarbonate at Day 15 Within the Combined TRC101 Treatment Group3.3 ± 0.2
Statistical analysis
  • Combined TRC101 · Mixed Models Analysis · p = < 0.0001 (The null hypothesis is that the mean change from baseline within the Combined TRC101 treatment group = 0 mEq/L.) · Group ls mean: 3.3 · 95% CI 3.0 to 3.7
SecondaryComparison of Change From Baseline in Serum Bicarbonate at Day 15 Between the Combined TRC101 Treatment Group Versus Placebo

Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the Combined TRC101 Treatment Group versus that for Placebo

Time frame:
Baseline and Day 15
Reported as:
Least squares mean · mEq/L
Comparison of Change From Baseline in Serum Bicarbonate at Day 15 Between the Combined TRC101 Treatment Group Versus Placebo
mEq/LPooled PlaceboCombined TRC101
Comparison of Change From Baseline in Serum Bicarbonate at Day 15 Between the Combined TRC101 Treatment Group Versus Placebo-0.2 ± 0.43.3 ± 0.2
Statistical analysis
  • Pooled Placebo vs Combined TRC101 · Mixed Models Analysis · p = < 0.0001 (The null hypothesis is that the difference between treatment groups (Combined TRC101 - Pooled Placebo) in the mean change from baseline = 0 mEq/L.) · Difference between group ls means: 3.6 · 95% CI 2.8 to 4.4
SecondaryComparison of the Proportion of Subjects Whose Serum Bicarbonate Values Increased From Baseline to Day 15 by Greater Than or Equal to 2, 3, or 4 mEq/L Between Each TRC101 Dose Group Versus Placebo

Comparison of the proportion of subjects whose serum bicarbonate values increased from Baseline to Day 15 by greater than or equal to 2, 3, or 4 mEq/L between each TRC101 BID Dose Group versus Placebo

Time frame:
Baseline and Day 15
Reported as:
Count of participants · Participants
Comparison of the Proportion of Subjects Whose Serum Bicarbonate Values Increased From Baseline to Day 15 by Greater Than or Equal to 2, 3, or 4 mEq/L Between Each TRC101 Dose Group Versus Placebo
ParticipantsPooled Placebo1.5g TRC101 BID3g TRC101 BID4.5g TRC101 BID
=> 2 mEq/L Baseline Serum Bicarbonate4181419
=> 3 mEq/L Baseline Serum Bicarbonate2141016
=> 4 mEq/L Baseline Serum Bicarbonate181011
Statistical analysis
  • Pooled Placebo vs 1.5g TRC101 BID · Fisher Exact · p = < 0.0001 (The null hypothesis is that the difference between treatment groups (1.5g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =\> 2 mEq/L = 0.)
  • Pooled Placebo vs 1.5g TRC101 BID · Fisher Exact · p = < 0.0001 (The null hypothesis is that the difference between treatment groups (1.5g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =\> 3 mEq/L = 0.)
  • Pooled Placebo vs 1.5g TRC101 BID · Fisher Exact · p = 0.0074 (The null hypothesis is that the difference between treatment groups (1.5g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =\> 4 mEq/L = 0.)
  • Pooled Placebo vs 3g TRC101 BID · Fisher Exact · p = 0.0012 (The null hypothesis is that the difference between treatment groups (3g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =\> 2 mEq/L = 0.)
  • Pooled Placebo vs 3g TRC101 BID · Fisher Exact · p = 0.0032 (The null hypothesis is that the difference between treatment groups (3g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =\> 3 mEq/L = 0.)
  • Pooled Placebo vs 3g TRC101 BID · Fisher Exact · p = 0.0013 (The null hypothesis is that the difference between treatment groups (3g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =\> 4 mEq/L = 0.)
  • Pooled Placebo vs 4.5g TRC101 BID · Fisher Exact · p = < 0.0001 (The null hypothesis is that the difference between treatment groups (4.5g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =\> 2 mEq/L = 0.)
  • Pooled Placebo vs 4.5g TRC101 BID · Fisher Exact · p = < 0.0001 (The null hypothesis is that the difference between treatment groups (4.5g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =\> 3 mEq/L = 0.)
  • Pooled Placebo vs 4.5g TRC101 BID · Fisher Exact · p = < 0.0006 (The null hypothesis is that the difference between treatment groups (4.5g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =\> 4 mEq/L = 0.)
SecondaryChange From Baseline in Serum Bicarbonate at Day 15 Within the TRC101 6g QD Dose Group

Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline

Time frame:
Baseline and Day 15
Reported as:
Least squares mean · mEq/L
Change From Baseline in Serum Bicarbonate at Day 15 Within the TRC101 6g QD Dose Group
mEq/L6g TRC101 QD
Change From Baseline in Serum Bicarbonate at Day 15 Within the TRC101 6g QD Dose Group3.5 ± 0.4
Statistical analysis
  • 6g TRC101 QD · Mixed Models Analysis · p = <0.0001 (The null hypothesis is that the mean change from baseline within the 6g TRC101 QD group = 0 mEq/L.) · Group ls mean: 3.5 · 95% CI 2.7 to 4.2
SecondaryChange From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus Placebo

Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the TRC101 6g dose group versus that for Placebo

Time frame:
Baseline and Day 15
Reported as:
Least squares mean · mEq/L
Change From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus Placebo
mEq/LPooled Placebo6g TRC101 QD
Change From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus Placebo-0.2 ± 0.43.5 ± 0.4
Statistical analysis
  • Pooled Placebo vs 6g TRC101 QD · Mixed Models Analysis · p = <0.0001 (The null hypothesis is the difference between treatment groups (6g TRC101 QD - Pooled Placebo) in the mean change from baseline = 0 mEq/L.) · Difference between group ls means: 3.7 · 95% CI 2.6 to 4.7
SecondaryChange From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus the TRC101 3g BID Dose Group

Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the TRC101 6g QD dose group versus that for the TRC101 3g BID dose group

Time frame:
Baseline and Day 15
Reported as:
Least squares mean · mEq/L
Change From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus the TRC101 3g BID Dose Group
mEq/L3g TRC101 BID6g TRC101 QD
Change From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus the TRC101 3g BID Dose Group3.0 ± 0.43.5 ± 0.4
Statistical analysis
  • 3g TRC101 BID vs 6g TRC101 QD · Mixed Models Analysis · p = 0.4214 (The null hypothesis is that the difference between treatment groups (3g TRC101 BID - 6g TRC101 QD) in the mean change from baseline = 0 mEq/L.) · Difference between group ls means: -0.5 · 95% CI -1.6 to 0.7
SecondaryComparison of the Proportion of Subjects in the TRC101 6g QD Dose Group Whose Serum Bicarbonate Values Increased From Baseline to Day 15 by Greater Than or Equal to 2, 3, or 4 mEq/L Versus Placebo

Comparison of the proportion of subjects whose serum bicarbonate values increased from Baseline to Day 15 by greater than or equal to 2, 3, or 4 mEq/L between the 6g TRC101 QD Dose Group versus Placebo

Time frame:
Baseline and Day 15
Reported as:
Count of participants · Participants
Comparison of the Proportion of Subjects in the TRC101 6g QD Dose Group Whose Serum Bicarbonate Values Increased From Baseline to Day 15 by Greater Than or Equal to 2, 3, or 4 mEq/L Versus Placebo
ParticipantsPooled Placebo6g TRC101 QD
=> 2 mEq/L Baseline Serum Bicarbonate423
=> 3 mEq/L Baseline Serum Bicarbonate214
=> 4 mEq/L Baseline Serum Bicarbonate112
Statistical analysis
  • Pooled Placebo vs 6g TRC101 QD · Fisher Exact · p = < 0.0001 (The null hypothesis is that the difference between treatment groups (6g TRC101 QD - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =\> 2 mEq/L = 0.)
  • Pooled Placebo vs 6g TRC101 QD · Fisher Exact · p = 0.0003 (The null hypothesis is that the difference between treatment groups (6g TRC101 QD - Pooled Placebo) in the proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =\> 3 mEq/L = 0.)
  • Pooled Placebo vs 6g TRC101 QD · Fisher Exact · p = 0.0003 (The null hypothesis is that the difference between treatment groups (6g TRC101 QD - Pooled Placebo) in the proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =\> 4 mEq/L = 0.)

Adverse events

Collected over Through treatment period completion (Day 15). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pooled Placebo0/31 (0%)0/31 (0%)12/31 (38.7%)
1.5g TRC101 BID0/25 (0%)0/25 (0%)13/25 (52%)
3g TRC101 BID0/25 (0%)0/25 (0%)9/25 (36%)
4.5g TRC101 BID0/26 (0%)0/26 (0%)17/26 (65.4%)
6g TRC101 QD0/28 (0%)0/28 (0%)13/28 (46.4%)
Most frequent other events
Most frequent other events
EventPooled Placebo1.5g TRC101 BID3g TRC101 BID4.5g TRC101 BID6g TRC101 QD
DiarrhoeaGastrointestinal disorders4/319/253/256/263/28
HeadacheNervous system disorders1/314/251/252/261/28
ConstipationGastrointestinal disorders0/311/251/252/263/28
HyperglycaemiaMetabolism and nutrition disorders0/310/252/252/263/28
Glomerular filtration rate decreasedInvestigations2/312/251/251/260/28
HypoglycaemiaMetabolism and nutrition disorders2/312/251/252/260/28
HypertensionVascular disorders1/311/250/252/262/28
Blood glucose increasedInvestigations2/311/250/250/261/28

Baseline characteristics

Intent-to-treat (ITT) population

Age, Continuous
Age, Continuous(years)Pooled Placebo1.5g TRC101 BID3g TRC101 BID4.5g TRC101 BID6g TRC101 QDTotal
Mean61 ± 1258 ± 1460 ± 1361 ± 1363 ± 1160.3 ± 12.44
Sex: Female, Male
Sex: Female, Male(Participants)Pooled Placebo1.5g TRC101 BID3g TRC101 BID4.5g TRC101 BID6g TRC101 QDTotal
Female1268111249
Male191917151686
Diabetes
Diabetes(Participants)Pooled Placebo1.5g TRC101 BID3g TRC101 BID4.5g TRC101 BID6g TRC101 QDTotal
Count of participants201820191794
Hypertension
Hypertension(Participants)Pooled Placebo1.5g TRC101 BID3g TRC101 BID4.5g TRC101 BID6g TRC101 QDTotal
Count of participants3024232326126
Heart Failure
Heart Failure(Participants)Pooled Placebo1.5g TRC101 BID3g TRC101 BID4.5g TRC101 BID6g TRC101 QDTotal
Count of participants7575529
Serum Bicarbonate
Serum Bicarbonate(mEq/L)Pooled Placebo1.5g TRC101 BID3g TRC101 BID4.5g TRC101 BID6g TRC101 QDTotal
Mean17.6 ± 1.418.0 ± 1.017.8 ± 1.217.5 ± 1.317.7 ± 1.017.72 ± 1.197
eGFR
eGFR(mL/min/1.73m^2)Pooled Placebo1.5g TRC101 BID3g TRC101 BID4.5g TRC101 BID6g TRC101 QDTotal
Mean34 ± 1435 ± 1340 ± 1335 ± 1331 ± 1035.70 ± 12.419
08

Study locations

5 sites
  • Investigative Site 1
    Sofia, Bulgaria
  • Investigative Site 3
    Tbilisi, Georgia
  • Investigative Site 4
    Tbilisi, Georgia
  • Investigative Site 5
    Tbilisi, Georgia
  • Investigative Site 6
    Tbilisi, Georgia
09

References and documents

Publications

  • Bushinsky DA, Hostetter T, Klaerner G, Stasiv Y, Lockey C, McNulty S, Lee A, Parsell D, Mathur V, Li E, Buysse J, Alpern R. Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD. Clin J Am Soc Nephrol. 2018 Jan 6;13(1):26-35. doi: 10.2215/CJN.07300717. Epub 2017 Nov 4. Erratum In: Clin J Am Soc Nephrol. 2019 Feb 7;14(2):277. doi: 10.2215/CJN.13671118. PubMed 29102959 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Nov 2016, 8 months.

Results were first posted in Jan 2020, 3 years 2 months after primary completion. A results delay was requested in Nov 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2016
First posted
Jun 22, 2016
StartActual
Mar 2016
Primary completionActual
Nov 2016
CompletionActual
Nov 2016
Results delay requested
Nov 30, 2017
Results first posted
Jan 14, 2020
Last update
Jan 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02809183
Lead sponsor
Tricida, Inc.
Responsible party
Sponsor
First posted
Jun 22, 2016
Start date
Mar 2016
Primary completion
Nov 2016
Completion
Nov 2016
Results posted
Jan 14, 2020
Last update
Jan 14, 2020

Study contacts

Yuri Stasiv, PhD
study director · Tricida, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Veverimer

Start the discussion